Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
133.2 SEK | +0.04% |
|
+6.30% | +21.76% |
07-05 | Sweden's AddLife Closes Purchase of Spanish Biotech Company BonsaiLab | MT |
07-05 | AddLife AB (OM:ALIF B) acquired Bonsailab SL. | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 67.54 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+21.76% | 1.55B | C | ||
+18.97% | 45.34B | B- | ||
+42.61% | 40.42B | A | ||
-10.06% | 37.92B | B | ||
+31.15% | 31.75B | B | ||
-7.79% | 27.71B | C | ||
+13.32% | 26.52B | B- | ||
+43.05% | 13.96B | B+ | ||
+31.28% | 12.44B | C+ | ||
-7.41% | 11.26B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALIF B Stock
- Ratings AddLife AB